Based in Bridgewater, New Jersey, VYNE Therapeutics Inc. is a pharmaceutical company that develops therapeutics for immuno-inflammatory conditions, such as acne vulgaris and mild-to-moderate atopic dermatitis. The company has completed Phase III clinical trials for its topical combination foam, FCD105, and its combination of tofacitinib, FMX114, is currently in Phase IIa preclinical trial. Additionally, VYNE Therapeutics Inc. is developing bromodomain and extra-terminal (BET) inhibitors, including VYN201 and VYN202, which have potential applications for various immuno-inflammatory diseases, including skin diseases.